CC BY-NC-ND 4.0 · Laryngorhinootologie 2018; 97(S 02): S89
DOI: 10.1055/s-0038-1640020
Abstracts
Onkologie: Oncology

Antibodies to tumor-associated antigens in non-recurrent and recurrent disease head and neck squamous cell carcinomas (HNSCC) patients

DS Gangkofner
1   Universitätsklinik Ulm, HNO-Klinik, Ulm
,
D Holzinger
2   DKFZ, Abteilung Molekulare Diagnostik onkogener Infektionen, Heidelberg
,
J Butt
2   DKFZ, Abteilung Molekulare Diagnostik onkogener Infektionen, Heidelberg
,
I Zörnig
3   NCT, DKFZ, Universitätsklinik Heidelberg, Heidelberg
,
M Broglie Däppen
4   Kantonsspital St. Gallen, HNO-Klinik, St. Gallen, Schweiz
,
G Dyckhoff
5   Universitätsklinik Heidelberg, HNO-Klinik, Heidelberg
,
P Boscolo-Rizzo
6   Universitätsklinik Padua, Abteilung für Neurowissenschaften, Treviso, Italien
,
G Wichmann
7   Universitätsklinik Leipzig, HNO-Klinik, Leipzig
,
M Pawlita
2   DKFZ, Abteilung Molekulare Diagnostik onkogener Infektionen, Heidelberg
,
S Laban
1   Universitätsklinik Ulm, HNO-Klinik, Ulm
› Author Affiliations
› Further Information
Also available at
 

Background:

Previously, we have discovered an association between MAGE-/NY-ESO-1 expression and poor overall survival in HNSCC patients. Using multiplex serology, we have now analyzed patterns of antibody (AB) responses to tumor-associated antigens (TAA) in non-recurrent (NR) and recurrent disease (RD) head and neck squamous cell carcinomas (HNSCC) patients.

Methods:

Plasma- and serum samples of 410 HNSCC patients treated at different cancer centers were analyzed for AB to 29 auto-antigens and HPV-16 E6 using multiplex serology. Among 319 patients with available recurrence status, 235 were NR and 84 had RD. Statistics: Antibody prevalences were compared using a Chi2-test. A correction for multiple testing was performed using the two-stage linear step-up procedure of Benjamini, Krieger and Yekutieli with a false discovery rate von 10%.

Results:

Among 235 NR patients, 82 (35%) were seropositive for HPV-16 E6. AB found most frequently were directed against MAGE-A3 (12%), MAGE-A4 (12%), SpanXa1 (11%), p53 (11%), and MAGE-A1 (10%). Among 84 RD pt, 18 (21%) were seropositive for HPV-16 E6. Antibody reactivity to MAGE-A3 (19%), MAGE-A4 (13%), SpanXa1 (12%), p53 (12%), MAGE-A1 (12%), c-myc (11%), Recoverin (11%) and MAGE-A9 (10%) was found most frequently. In RD patients, AB against MAGE-C2 were significantly more frequent (NR: 2% vs. RD: 8%; p = 0.010, Chi2-Test) and AB to HPV-16 E6 significantly less frequent (p = 0.014). Corrected for multiple testing, the p-values did not reach significance.

Conclusions:

AB to TAA in NR and RD patients are directed against the same antigens. Data analysis is ongoing.



Publication History

Publication Date:
18 April 2018 (online)

© 2018. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Georg Thieme Verlag KG
Stuttgart · New York